Patients affected with multiple myeloma constitute an heterogeneous population with very different clinical patterns, varying from asymptomatic to very compromised patients with severe and uncontrolled disease. Most common clinical and biological staging systems have been in use for many years. Recently new prognostic factors have been identified; among them, serum levels of beta-2 microglobuline, C-reactive protein and interleukine-6 employed with already known parameters have been useful in the new staging system, permitting a more focalized therapy. As today is not yet possible to define the best treatment schedule, as the most common treatments are incapable to eradicate myeloma neoplastic clone even in responsive patients. Nevertheless extensive use of biologic response modifiers in the last years, as alpha interferon, have added new powerful and hopeful therapeutic tools even if the results need to be confirmed in future trials. It's important to remind the primary role of bone marrow transplantation associated with high dose polichemiotherapy even if just a minority of patients is eligible for this therapeutic chance.

Il mieloma multiplo. Ruolo dei fattori prognostici e della stadiazione in un programma terapeutico / S. Bolis, E.R. Bregani, F. Rossini, I. Casaroli, E. Lanzi, P. Maffè, L. Borin, S. Mingozzi, P. Tripputi, E.M. Pogliani, G. Corneo. - In: RECENTI PROGRESSI IN MEDICINA. - ISSN 0034-1193. - 85:1(1994), pp. 49-55.

Il mieloma multiplo. Ruolo dei fattori prognostici e della stadiazione in un programma terapeutico

P. Tripputi;
1994

Abstract

Patients affected with multiple myeloma constitute an heterogeneous population with very different clinical patterns, varying from asymptomatic to very compromised patients with severe and uncontrolled disease. Most common clinical and biological staging systems have been in use for many years. Recently new prognostic factors have been identified; among them, serum levels of beta-2 microglobuline, C-reactive protein and interleukine-6 employed with already known parameters have been useful in the new staging system, permitting a more focalized therapy. As today is not yet possible to define the best treatment schedule, as the most common treatments are incapable to eradicate myeloma neoplastic clone even in responsive patients. Nevertheless extensive use of biologic response modifiers in the last years, as alpha interferon, have added new powerful and hopeful therapeutic tools even if the results need to be confirmed in future trials. It's important to remind the primary role of bone marrow transplantation associated with high dose polichemiotherapy even if just a minority of patients is eligible for this therapeutic chance.
alpha-interferon; beta-2 microglobuline; C-reactive protein; interleukine 6; multiple myeloma
Settore MED/09 - Medicina Interna
Settore MED/15 - Malattie del Sangue
1994
Article (author)
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/204342
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 0
  • ???jsp.display-item.citation.isi??? ND
social impact